AllianceBernstein (NYSE:AB) was downgraded at TD Cowen after Equitable Holdings (NYSE:EQH) announced a tender offer for up to ...
TD Cowen initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and no price target The company’s MZE829, and oral APOL1 inhibitor, ...
MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25New ...
Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage ...
The report raised fears about the sustainability of AI infrastructure growth. That could mean less demand for Nvidia's chips.
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...
ST. LOUIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for ...
TD Cowen analyst Andrew Kligerman maintained a Buy rating on Abacus Life (ABL – Research Report) today and set a price target of $14.00. The ...